PNPLA2

Across TCGA pan-cancer cohorts, PNPLA2 RNA differs between tumor and matched normal tissue in 13 of 18 cancer types tested, making tumor–normal expression one of PNPLA2’s most consistent transcriptional readouts.

The strongest signal is observed in breast invasive carcinoma (BRCA), where PNPLA2 RNA is repressed in tumor relative to normal tissue. In most cancer types PNPLA2 is over-expressed in tumor, although a few such as BRCA and LUAD show the opposite, repressed pattern.

BRCA, LUAD, and LIHC are the cancer types where PNPLA2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PNPLA2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BRCA	All	II,III,IV	−1.689	<.001	8	view →
LUAD	Male	All	−1.007	<.001	8	view →
LIHC	Female	All	+0.724	<.001	8	view →
LUSC	Female	II,III,IV	−1.334	<.001	7	view →
KICH	Male	All	−1.179	<.001	7	view →
STAD	All	II,III,IV	+0.475	.015	5	view →
THCA	Male	All	+0.432	<.001	4	view →
UCEC	All	All	−0.424	.017	4	view →
ESCA	All	II,III,IV	+0.839	.031	3	view →
CHOL	Male	All	+1.413	<.001	2	view →
READ	Male	All	−0.636	.039	2	view →
KIRC	All	All	+0.270	.008	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 13 lineages.

PNPLA2–BRCA

Open the BRCA breakdown →